The secondary endpoints , including a change in the frequency of chest pain ( -@ vs -@ , respectively , p = @ ) , a change in the chest pain severity scale ( -@ vs -@ , respectively , p = @ ) , and the proportion of chest pain-free patients ( @ % vs @ % , respectively , p = @ ) also significantly favoured cilostazol .